10
MNiSW
71.22
ICV
REVIEW PAPER
 
CC BY-NC-ND 3.0
 
 

Herbal medicine for treatment and prevention of liver diseases

Andrzej Prystupa 2  ,  
 
1
Research Students’ Association, Medical University, Lublin, Poland
2
Department of Internal Medicine, Medical University of Lublin,Poland
3
Department of Nephrology, Medical University of Lublin.
4
Institute of Rural Health, Poland
JPCCR 2014;8(2):55–60
KEYWORDS:
ABSTRACT:
The rising number of patients with liver dysfunction due to overwhelming usage of drugs and alcohol has paved the path for researchers in an interest in herbal medicine. This is because there are only a few universally effective and available options for the treatment of common liver diseases, such as cirrhosis, fatty liver and chronic hepatitis. Herbal treatment has been used to alleviate disorders related to liver and other internal organs for many centuries in the eastern world, and have currently become a favourable therapy internationally for pathological liver conditions. In recent years, researchers have used scientific methods to evaluate the effects of plants for the treatment of liver ailments, although in many cases the mechanisms and modes of action of these plants, as well as their therapeutic effectiveness, have not been confirmed. Several hundred plants have been examined to-date, but only a handful has been studied thoroughly. Among these, the current study discusses a compilation of herbal medicines used for liver protection, such as Silymarin (milk thistle), Liv-52, Camellia sinensis (green tea), Glycyrrhizaglabra (licorice) and FuzhengHuayu. The increasing use of herbal medicines reflects their perceived effectiveness in the treatment and prevention of disease, and the belief that these treatments are safe because they are ‘natural’. The presented study evaluates the effects of herbal extracts in the treatment of liver diseases, provides a general understanding of the actions of herbal medicines, a background for understanding the hepato-protectiveness of herbs, and the challenges that are faced by the scientific community in researching thoroughly of each and every compounds of the herbs.
CORRESPONDING AUTHOR:
Andrzej Prystupa   
Chair and Department of Internal Medicine, Medical University, Staszica 16, 20-081 Lublin, Poland
 
REFERENCES:
1. Dey P, Saha MR, Sen A. Hepatotoxicity and the present herbal hepatoprotective scenario. Int J Green Pharm. 2013; 7: 265–273.
2. Abeloff MD, et al. Abeloff’s Clinical Oncology, 4th ed. Philadelphia, PA: Churchill Livingstone, An Imprint of Elsevier. 2008.
3. Efferth T, Kaina B. Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine. Curr Drug Metab. 2011; 12(10): 989–996.
4. Hasan SS, Ahmed SI, Bukhari NI, Loon WC. Use of complementary and alternative medicine among patients with chronic diseases at outpatient clinics. Complement Ther Clin Pract. 2009; 15(3): 152–157.
5. Ansari JA. Therapeutic Approaches in Management of Drug-induced Hepatotoxicity. J Biol Sci. 2010; 10: 386–395.
6. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001; 24: 483–490.
7. Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol. 2009; 15(28): 3462–3471.
8. Duryee MJ, Klassen LW, Thiele GM, Immunological response in alcoholic liver disease. World J Gastroenterol. 2007; 13(37): 4938–4946.
9. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis. 2008; 28(4): 370–379.
10. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41(2): 353–358.
11. Beasley RP, Hwang L-Y: Overview on the epidemiology of hepatocellularcarcinoma. 532 In: Hollinger FB, Lemon SM, Lemon SM, Margolis HS, (eds). Viral Hepatitis and Liver Disease. Williams and Wilkins, Baltimore, 1991.
12. Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis- -United States, 2006. MMWR Surveill Summ. 2008; 57(2): 1–24.
13. Samudram P, Rajeshwari H, Vasuki R, Geetha A, Sathiya moorthi P. Hepatoprotective activity of Bi-herbal ethanolic extract on CCl4 induced hepatic damage in rats. Afr J Biochem Res. 2008; 2(2): 61–65.
14. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol. 2008; 14(2): 193–199.
15. Hye-Lin Ha, Hye-Jun Shin, Mark A Feitelson, Dae-Yeul Yu. Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol. 2010; 16(48): 6035–6043.
16. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev. 1998; 3: 410–21.
17. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006; 124(5): 491–504.
18. Féher J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol. 2012; 13(1): 210–217.
19. Agency for Healthcare Research and Quality. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Summary, evidence report/technology assessment: number 21, September 2000.
20. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001; 61: 2035–2063.
21. vanRossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Glycyrrhizin as a potential treatment for chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2003; 12(3): 199–205. doi:10.1046/j.1365–2036.1998.00309.x. PMID 9570253.
22. Charak S. Vimanasthan. Chapter I (2,3). Translated by P.V. Sharma, ChaukhambaOrientalia Publishers, Varanasi, 1981.p. 305.
23. Vyas KJ. Treatment of Hepatopathy in Children with a Combination of Capparis Spinosa and Other Indian Indigenous Drugs. Children Ward, General Hospital, Junagadh, Gujarat. Medical Digest 1961; 29(3): 105–112.
24. Warrier PK, Nambiar VPK, Ramankutty C. Indian Medicinal 346 Plants A compendium of 500 species. Orient Longman India. 1994; 1: 349–351.
25. Ciesek S, Von Hahn T, Colpitts ChC, Schang LM, Friesland M, Steinmann J, Manns MP, Ott M, Wedemeyer H, Meuleman P, Pietschmann T, Steinmann E. The Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) Inhibits Hepatitis C Virus (HCV) Entry. Sandra Ciesek, Thomas von Hahn, Che C. Colpitts, Luis M Schang, Martina Friesland, Jörg Steinmann, Michael P. Manns, Michael Ott, HeinerWedemeyer, Philip Meuleman, Thomas Pietschmann and Eike Steinmann. Hepatology. 2011. http://onlinelibrary.wiley.com/doi/10.1002/hep.24610/abstract (access: 2014.11.05). doi: 10.1002/hep.24610.
26. Ahmad N, Mukhtar H. Green tea polyphenols and cancer; bio-364 logic mechanism and practical implications. Nutr Rev. 1999; 57: 365, 378–383.
27. Jin X, Zheng RH, Li YM. Green tea consumption and liver disease: a systematic review. Liver Int. 2008; 28(7): 990–996.
28. Rajesh MG, Latha MS. Protective activity of Glycyrrhiza glabra Linn. on carbon tetrachloride-induced peroxidative damage. Indian J Pharmacol. 2004; 36: 284–287.
29. Sato H, Goto W, Yamamura J, Kurokawa M, Kageyama S, Takahara T, Watanabe A, Shiraki K. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res. 1996 May; 30(2–3): 171–177. doi:10.1016/0166-3542(96)00942-4. PMID 8783808.
30. Strandberg TE, Andersson S, Jarvenpaa AL, et al. Preterm birth and licorice consumption during pregnancy. Am J Epidemiol. 2002;156(9): 803–805.
31. Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79(8): 1494–1500.
32. Liu P, Liu C, Chen GC, Hu YY, Xu LM, Lv P, Yang JL, Yan RM, Ji Q, Chu F. Effect of Fuzheng Huayu 319 recipe on serological parameters of fibrosis in treating chronic hepatitis B. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1996; 16: 588–592.
33. Cui AL. Treatment of 54 cases of active hepatocirrhosis with lamivudine combined with Fu Zheng Hua Yu capsule. Journal of China Pharmaceutical. 2012; 21: 74–75.
eISSN:1898-7516
ISSN:1898-2395